‘We started the first trial in 2002 and we finished the efficacy trial in 2013.’ Nine years of trials. That was on top of the time taken to develop the thing in the first place. That’s a long time. For Le Mans, the MdS and the Vendee Globe, the finish line is known, fixed; for vaccines, new data may move the finish line at any time. Vaccine development may not be as physically demanding, but to keep plugging away for twenty years surely requires mental resilience.
Jenner scientist Dr Rachel Tanner has been awarded an NC3Rs Skills and Knowledge Transfer Grant for the transfer of a novel non-human primate in vitro mycobacterial growth inhibition assay. The assay will be transferred to Public Health England and the Biomedical Primate Research Centre, with the aim of refining and reducing use of non-human primate TB infection models in the early evaluation of TB vaccine candidates.
A mycobacterial growth inhibition assay (MGIA) for bovine TB vaccine development Tuberculosis, 106, pp. 118-122. Article
Adjuvanting a viral vectored vaccine against pre-erythrocytic malaria. Sci Rep, 7 (1), pp. 7284. Article
Clinical trials are an essential part of vaccine development, and our volunteers play a critical role in our studies.
If you would like to find out more about paid clinical trials, and what is involved in participating, please go to our Recruiting Trials page to see which trials are currently recruiting.
Prof Vincenzo Cerundolo: Amino acid degrading enzymes and their role in tumour immune escape mechanisms, 15/Sep/2017 14:00